Entresto Patent Order Quashed In India, Market Ripe For Action

Court sets aside order pertaining to patent for Novartis’s Entresto in India, setting the stage for high-octane generic competition that potentially includes frontline domestic companies. If the Swiss firm appeals, market dynamics may be impacted but prices of same-composition second brands of the heart-failure therapy are already headed southwards.